Remarkably, patients with both high nuclear Tak1 expression and low nuclear Cyld levels in HCC tissue, probably resembling the group with the most potent activation of the Cyld-Tak1 pathway, had a very short overall survival (Figure 5a). The gene discussed is CYLD; the disease is hepatocellular carcinoma.